
News|Articles|May 1, 2006
Pipeline Preview (May 2006)
Approvable designations
Advertisement
Approvable designations
• Sitaxsentan (Thelin, Encysive Pharmaceuticals) for the treatment of pulmonary arterial hypertension
Fast-track designations
Priority review
• Infliximab (Remicade, Centocor) for pediatric Crohn's disease
Orphan drug designations
• Cell-permeable peptide (AM-111, Auris Medical) for acute sensorineural hearing loss
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Global MS analysis links disability burden to rising economic strain
2
HS patients on biosimilar adalimumab lose response faster than those on the original drug
3
New drug class shows promise for geographic atrophy
4
CMS negotiates a 70% discount for Ozempic and Wegovy
5






















































